Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2258903 | 0.92 | TRPV1 (0.47) | P2RX7TRPV1TGFBR1POLBTSHR | |
| SCHEMBL2259409 | 0.91 | TGFBR1 (0.41) | P2RX7TRPV1TGFBR1TSHR | |
| SCHEMBL2262135 | 0.88 | HCRTR1 (0.49) | P2RX7TRPV1TGFBR1POLBTSHR | |
| SCHEMBL2261025 | 0.88 | TRPV1 (0.47) | P2RX7TRPV1TGFBR1POLBTSHR | |
| SCHEMBL2257644 | 0.87 | POLB (0.45) | P2RX7TRPV1TGFBR1POLBTSHR | |
| SCHEMBL2260645 | 0.86 | TRPV1 (0.49) | P2RX7TRPV1TSHR | |
| SCHEMBL2260391 | 0.86 | TGFBR1 (0.43) | P2RX7TRPV1TGFBR1TSHR | |
| SCHEMBL2258107 | 0.86 | P2RX7 (0.58) | P2RX7TRPV1 | |
| SCHEMBL2256831 | 0.85 | TRPV1 (0.52) | P2RX7TRPV1TGFBR1 | |
| SCHEMBL2255449 | 0.85 | NPSR1 (0.51) | P2RX7TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | P2RX7 797/4885TRPV1 1100/4885TGFBR1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.